Does Pfizer Have a Bright Future?

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

With shares of Pfizer (NYSE:PFE) trading around $31, is PFE an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let’s analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

Pfizer is a biopharmaceutical company that discovers, develops, manufactures, and sells medicines for people and animals worldwide. The company manages its operations through five segments: Primary Care, Specialty Care and Oncology, Established Products and Emerging Markets, Animal Health and Consumer Healthcare, and Nutrition. Pfizer’s main products include human and animal biologic and small molecule medicines, as well as vaccines, nutritional products, consumer healthcare products, and products for the prevention and treatment of diseases in livestock and companion animals.

The U.S. Supreme Court on Monday rejected an appeal from Pfizer, leaving in place a $142 million settlement the pharmaceutical company must pay to the Kaiser Foundation on the grounds that Pfizer falsely marketed an epilepsy drug called Neurontin. The Supreme Court is also allowing two other lawsuits on the same issue to continue forward, according to a report from Bloomberg. Pfizer allegedly marketed the drug as a treatment for migraines, manic-depressive issues, and neuropathic pain when it was not approved by the Food and Drug Administration for those uses.

More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business